Alycia Gardner

Alycia Gardner

Auto-generated profile, based on publicly available information

Alycia Gardner

Brigham and Women’s Hospital 1 Genetics Division, Department of Medicine Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in Trends in Immunology
Verified
Journal Article
Closed access
AGAlycia Gardner
Alycia Gardner
BRBrian Ruffell
Brian Ruffell

1 January 2018 in Cancer Cell
Verified
Journal Article
Closed access
ÁPÁlvaro de Mingo Pulido
Álvaro de Mingo Pulido
AGAlycia Gardner
Alycia Gardner
SHShandi Hiebler
Shandi Hiebler
HSHatem Soliman
Hatem Soliman
HRHope S. Rugo
Hope S. Rugo
BRBrian Ruffell
Brian Ruffell

1 June 2021 in Immunity
Verified
Journal Article
Closed access
ÁPÁlvaro de Mingo Pulido
Álvaro de Mingo Pulido
KHKay Hänggi
Kay Hänggi
DCDaiana P. Celias
Daiana P. Celias
AGAlycia Gardner
Alycia Gardner
JLJie Li
Jie Li
BRBrian Ruffell
Brian Ruffell

9 October 2024 in Nature
Verified
Journal Article
Open access
PDF file
ASAmy E. Schade
Amy E. Schade
Naiara PerurenaNaiara Perurena
Naiara Perurena
YYYoona Yang
Yoona Yang
CRCarrie L. Rodriguez
Carrie L. Rodriguez
AKAnjana Krishnan
Anjana Krishnan
KCKaren Cichowski
Karen Cichowski
Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype and has the highest rate of recurrence1. The predominant standard of care for advanced TNBC is systemic chemotherapy with or without immunotherapy; however, responses are typically short lived1,2. Thus, there is an urgent need to develop more effective treatments. Components of the PI3K pathway represent plausible therapeutic targets; more than 70% of TNBCs have alterations in PIK3CA, AKT1 or PTEN3,4,5,6. However, in contrast to hormone-receptor-positive tumours, it is still unclear whether or how triple-negative disease will respond to PI3K pathway inhibitors7. Here we describe a promising AKT-inhibitor-based therapeutic combination for TNBC. Specifically, we show that AKT inhibitors synergize with agents that suppress the histone methyltransferase EZH2 and promote robust tumour regression in multiple TNBC models in vivo. AKT and EZH2 inhibitors exert these effects by first cooperatively driving basal-like TNBC cells into a more differentiated, luminal-like state, which cannot be effectively induced by either agent alone. Once TNBCs are differentiated, these agents kill them by hijacking signals that normally drive mammary gland involution. Using a machine learning approach, we developed a classifier that can be used to predict sensitivity. Together, these findings identify a promising therapeutic strategy for this highly aggressive tumour type and illustrate how deregulated epigenetic enzymes can insulate tumours from oncogenic vulnerabilities. These studies also reveal how developmental tissue-specific cell death pathways may be co-opted for therapeutic benefit.

23 January 2023 in Nature Cancer
Verified
Journal Article
Open access
PDF file
DLDaniel K. Lester
Daniel K. Lester
CBChase Burton
Chase Burton
AGAlycia Gardner
Alycia Gardner
PIPatrick Innamarato
Patrick Innamarato
KKKrithika Kodumudi
Krithika Kodumudi
ELEric Lau
Eric Lau
Immunotherapy efficacy is limited in melanoma, and combinations of immunotherapies with other modalities have yielded limited improvements but also adverse events requiring cessation of treatment. In addition to ineffective patient stratification, efficacy is impaired by paucity of intratumoral immune cells (itICs); thus, effective strategies to safely increase itICs are needed. We report that dietary administration of l-fucose induces fucosylation and cell surface enrichment of the major histocompatibility complex (MHC)-II protein HLA-DRB1 in melanoma cells, triggering CD4+ T cell-mediated increases in itICs and anti-tumor immunity, enhancing immune checkpoint blockade responses. Melanoma fucosylation and fucosylated HLA-DRB1 associate with intratumoral T cell abundance and anti-programmed cell death protein 1 (PD1) responder status in patient melanoma specimens, suggesting the potential use of melanoma fucosylation as a strategy for stratifying patients for immunotherapies. Our findings demonstrate that fucosylation is a key mediator of anti-tumor immunity and, importantly, suggest that l-fucose is a powerful agent for safely increasing itICs and immunotherapy efficacy in melanoma.

12 August 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
PLPatrick Loi
Patrick Loi
ASAmy E. Schade
Amy E. Schade
CRCarrie L. Rodriguez
Carrie L. Rodriguez
AKAnjana Krishnan
Anjana Krishnan
Naiara PerurenaNaiara Perurena
Naiara Perurena
KCKaren Cichowski
Karen Cichowski
Current treatments for KRAS-mutant colorectal cancers are often limited by cellular plasticity and rewiring responses. Here we describe a promising therapeutic strategy that simultaneously targets epigenetic and oncogenic signals. Specifically, we show that inhibitors of histone methyltransferase, EZH2, synergize with various rat sarcoma virus (RAS) pathway inhibitors and promote dramatic tumor regression in vivo. Together these agents cooperatively suppress Wingless and Int-1 (WNT)-driven transcription and drive colorectal cancers into a more differentiated cell state by inducing the Groucho/transducin-like enhancer corepressor, TLE4, along with a network of WNT pathway inhibitors and intestinal differentiation proteins. However, these agents also induce the proapoptotic protein BCL2 modifying factor (BMF), which subsequently kills these more differentiated cells. Accordingly, cell death can be prevented by activating β-catenin, by blocking differentiation, or by ablating BMF expression. Collectively, these studies reveal a new therapeutic approach for treating KRAS-mutant colorectal cancers and illustrate a critical convergence of EZH2 and RAS on oncogenic WNT signals, intestinal differentiation, and apoptosis. Significance: Combined EZH2 and RAS pathway inhibitors kill KRAS-mutant colorectal cancer cells and promote durable tumor regression in vivo. These agents function by cooperatively suppressing the WNT pathway, driving differentiation, and epigenetically reprogramming cells to permit the induction of apoptotic signals, which then kill these more differentiated tumor cells.